Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01 · 8-K

Exact Sciences Corporation

Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Material Modification to Rights of Security Holders · Changes in Control of Registrant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 1.01 Entry into a Material Definitive Agreement. Exact has outstanding 0.3750% Convertible Senior Notes due 2027 (the “2027 Notes”), 0.3750% Convertible Senior Notes due 2028 (the “2028 Notes”), 2.00% Convertible Senior Notes due 2030 (the “2030 Notes”) and 1.75% Convertible Senior Notes due 2031 (the “2031 Notes” and, together with the 2027 Notes, the 2028 Notes and the 2030 Notes, the “Notes”).…

Filed Mar 23, 2026Accepted Mar 23, 2026, 9:00 AM EDTCIK 1124140Accession 0001193125-26-118700
Share

Company context

Exact Sciences’ Precision Oncology portfolio delivers actionable genomic insights to inform prognosis and cancer treatment after a diagnosis. In breast cancer, the Oncotype DX Breast Recurrence Score® test is the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. The Oncotype DX test is recognized as the standard of care and is included in all major breast cancer treatment guidelines. The OncoExTra® test applies comprehensive tumor profiling, utilizing whole exome and whole transcriptome sequencing, to aid in therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. With an extensive panel of approximately 20,000 genes and 169 introns, the OncoExTra test is one of the most comprehensive genomic (DNA) and transcriptomic (RNA) panels available today. Exact Sciences enables patients to take a more active role in their cancer care and makes it easy for providers to order tests, interpret results, and personalize medicine, by applying real-world evidence and guideline recommendations. To learn more, visit precisiononcology.exactsciences.com.

Historical securities (1)

Recent company filings

  1. 15-12G filingApr 2, 2026
  2. POSASR filingMar 23, 2026
  3. S-8 POS filingMar 23, 2026
  4. S-8 POS filingMar 23, 2026
  5. S-8 POS filingMar 23, 2026

Registered securities in this filing

EXACT SCIENCES CORP · 8-K · Filed 2026-03-23

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.01 par value per share

Symbol
EXAS
Exchange
NASDAQ
Classification
COMMON
Status
Historical · closed Mar 23, 2026
Filing context

Context: duration_2026-03-23_to_2026-03-23

Dimensions: Not supplied

Accession 000119312526118700 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement. Exact has outstanding 0.3750% Convertible Senior Notes due 2027 (the “2027 Notes”), 0.3750% Convertible Senior Notes due 2028 (the “2028 Notes”), 2.00% Convertible Senior Notes due 2030 (the “2030 Notes”) and 1.75% Convertible Senior Notes due 2031 (the “2031 Notes” and, together with the 2027 Notes, the 2028 Notes and the 2030 Notes, the “Notes”). On March 23, 2026, Exact and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as trustee (the “Trustee”), entered into the Sixth Supplemental Indenture with respect to the 2027 Notes (the “2027 Supplemental Indenture”), the Seventh Supplemental Indenture with respect to the 2028 Notes (the “2028 Supplemental Indenture”), the Eighth Supplemental Indenture with respect to the 2030 Notes (the “2030 Supplemental Indenture”) and the Ninth Supplemental Indenture with respect to the 2031 Notes (the “2031 Supplemental Indenture” and, together with the 2027 Supplemental Indenture, the 2028 Supplemental Indenture and the 2030 Supplemental Indenture, the “Supplemental Indentures”). Each of the Supplemental Indentures is a supplemental indenture under the indenture between Exact and the Trustee dated as of January 17, 2018. As a result of the Merger, and pursuant to the Supplemental Indentures, at and after the effective time of the Merger (the “Effective Time”), the right to convert each $1,000 principal amount of the Notes was changed to a right to convert such principal amount of the Notes into solely cash in an amount equal to the conversion rate of the applicable Notes then in effect multiplied by $105.00. The foregoing description of the Notes and the Supplemental Indentures does not purport to be complete and is subject to, and qualified in its entirety by reference to, the 2027 Supplemental Indenture, the 2028 Supplemental Indenture, the 2030 Supplemental Indenture and the 2031 Supplemental Indenture, copies of which are attached hereto as Exhibit 4.1, Exhibit 4.2, Exhibit 4.3 and Exhibit 4.4, respectively, and incorporated herein by reference.
Item 1.02Item 1.02 - Termination of Material Agreement
Item 1.02 Termination of a Material Definitive Agreement. On March 23, 2026, Exact repaid in full any outstanding principal and paid any accrued and unpaid interest (together with all fees, expenses and other amounts owed in connection therewith), and effectuated the release of all liens securing any obligations and the release of all guarantees, under the Credit Agreement, dated as of January 13, 2025, among Exact, the lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as administrative agent.
Item 2.01Item 2.01 - Completion of Acquisition
Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the Introductory Note and in Items 3.03, 5.01 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. In accordance with the terms of the Merger Agreement, on March 23, 2026, at the Effective Time, Merger Sub merged with and into Exact, with Exact surviving the Merger as a direct, wholly owned subsidiary of Abbott. At the Effective Time, pursuant to the Merger Agreement, each share of Exact’s common stock, par value $0.01 per share (“Common Stock”) (other than dissenting shares and certain excluded shares), issued and outstanding immediately prior to the Effective Time, was converted into the right to receive $105.00 in cash, without interest (the “Per Share Merger Consideration,” and the aggregate Per Share Merger Consideration for all such shares of Common Stock, the “Merger Consideration”), less any applicable withholding taxes. At the Effective Time: Each option to purchase shares of Common Stock granted under an Exact stock plan that was outstanding and unexercised as of immediately prior to the Effective Time, all of which were vested, was cancelled and, in the case of any such option the per-share exercise price of which was less than the Per Share Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of t... Each share of Common Stock subject to vesting, repurchase or other lapse restriction granted under an Exact stock plan that was outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Per Share Merger Consideration, subject to any applicable tax withholding. Each restricted stock unit award, deferred stock unit award and performance share unit award granted under an Exact stock plan that was outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of the date of the Merger Agreement, and was cancelled and converted into the right to receive the Per Share Merger Consideration in respect of each s...
Item 3.01Item 3.01 - Notice of Delisting
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The information set forth in the Introductory Note and in Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.01. On March 23, 2026, Exact notified The Nasdaq Stock Market LLC (the “Nasdaq”) that the Merger had been completed and requested that the Nasdaq file with the SEC a notification of removal from listing and registration on Form 25 to effect the delisting of all shares of Common Stock from the Nasdaq and the deregistration of Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As a result, the Common Stock will no longer be listed on the Nasdaq. Trading of Common Stock on the Nasdaq was halted prior to the opening of trading on March 23, 2026. Exact intends to file a certification on Form 15 with the SEC to suspend its reporting obligations under Sections 13 and 15(d) of the Exchange Act.
Item 3.03Item 3.03 - Material Modification to Rights
Item 3.03 Material Modification to Rights of Security Holders. The information set forth in the Introductory Note and in Items 2.01, 3.01 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03. At the Effective Time, each holder of Common Stock issued and outstanding immediately prior to the Effective Time ceased to have any rights with respect to such holder’s shares of Common Stock, except the right to receive the Per Share Merger Consideration in accordance with the Merger Agreement or, in the case of dissenting shares, such consideration as may be determined pursuant to Section 262 of the General Corporation Law of the State of Delaware.
Item 5.01Item 5.01 - Changes in Control
Item 5.01 Changes in Control of Registrant. The information set forth in the Introductory Note and in Items 2.01, 3.03 and 5.02 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01. As a result of the Merger, on March 23, 2026, a change in control of Exact occurred, and Exact is now a direct, wholly owned subsidiary of Abbott. The Merger Consideration was approximately $21 billion, which was funded through a combination of cash on hand and proceeds from debt financing. The Merger Consideration does not include the cash that may become payable upon conversion of the Notes.
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The information set forth in the Introductory Note and in Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.02. In accordance with the Merger Agreement, effective as of the Effective Time, Kevin Conroy, Michael Barber, Paul Clancy, D. Scott Coward, James Doyle, Shacey Petrovic, Kimberly Popovits, Leslie Trigg and Katherine Zanotti, comprising the members of Exact’s Board of Directors (the “Board of Directors”) immediately prior to the Effective Time, resigned from the Board of Directors and the committees of the Board of Directors, if any, on which they served. By virtue of the Merger, all of the officers of Exact ceased to hold their respective positions with Exact, effective as of the Effective Time.
Item 5.03Item 5.03 - Amendments to Articles/Bylaws
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. The information set forth in the Introductory Note and in Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.03. At the Effective Time, the certificate of incorporation and bylaws of Exact were each amended and restated in their entirety as set forth in Exhibit 3.1 and Exhibit 3.2, respectively, to this Current Report on Form 8-K, which exhibits are incorporated by reference into this Item 5.03.
Filed exhibits (4)
EX-4.1 (by filename) d128802dex41.htm

EX-4.1 4 d128802dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 SIXTH SUPPLEMENTAL INDENTURE THIS SIXTH SUPPLEMENTAL INDENTURE (this “Sixth Supplemental Indenture”) dated as of March 23, 2026 between Exact Sciences Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as trustee (the “Trustee”). W I T N E S S E T H : WHEREAS, the Company and the Trustee are parties to an Indenture, dated as of January 17, 2018 (the “Base Indenture”), and the Second Supplemental Indenture, dated as of March 8, 2019 (the “Second Supplemental Indenture”, together with the Base Indenture, the “2027 Notes Indenture”) providing for the issuance of the 0.3750% Convertible Senior Notes due 2027 (the “Notes”); WHEREAS, the Company entered into that certain Agreement and Plan of Merger, dated as of November 19, 2025 (the “Merger Agreement”), by and among the Company, Abbott Laboratories, an Illinois corporation (“Abbott”), and Badger Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Abbott (“Merger Sub”), pursuant to which, on the terms and subject to the conditions set forth i…

Open exhibit ↗
EX-4.2 (by filename) d128802dex42.htm

EX-4.2 5 d128802dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 SEVENTH SUPPLEMENTAL INDENTURE THIS SEVENTH SUPPLEMENTAL INDENTURE (this “Seventh Supplemental Indenture”) dated as of March 23, 2026 between Exact Sciences Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as trustee (the “Trustee”). W I T N E S S E T H : WHEREAS, the Company and the Trustee are parties to an Indenture, dated as of January 17, 2018 (the “Base Indenture”), and the Third Supplemental Indenture, dated as of February 27, 2020 (the “Third Supplemental Indenture”, together with the Base Indenture, the “2028 Notes Indenture”) providing for the issuance of the 0.3750% Convertible Senior Notes due 2028 (the “Notes”); WHEREAS, the Company entered into that certain Agreement and Plan of Merger, dated as of November 19, 2025 (the “Merger Agreement”), by and among the Company, Abbott Laboratories, an Illinois corporation (“Abbott”), and Badger Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Abbott (“Merger Sub”), pursuant to which, on the terms and subject to the conditions set…

Open exhibit ↗
EX-4.3 (by filename) d128802dex43.htm

EX-4.3 6 d128802dex43.htm EX-4.3 EX-4.3 Exhibit 4.3 EIGHTH SUPPLEMENTAL INDENTURE THIS EIGHTH SUPPLEMENTAL INDENTURE (this “Eighth Supplemental Indenture”) dated as of March 23, 2026 between Exact Sciences Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). W I T N E S S E T H : WHEREAS, the Company and the Trustee are parties to an Indenture, dated as of January 17, 2018 (the “Base Indenture”), and the Fourth Supplemental Indenture, dated as of March 1, 2023 (the “Fourth Supplemental Indenture”, together with the Base Indenture, the “2030 Notes Indenture”) providing for the issuance of the 2.0% Convertible Senior Notes due 2030 (the “Notes”); WHEREAS, the Company entered into that certain Agreement and Plan of Merger, dated as of November 19, 2025 (the “Merger Agreement”), by and among the Company, Abbott Laboratories, an Illinois corporation (“Abbott”), and Badger Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Abbott (“Merger Sub”), pursuant to which, on the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub merged with an…

Open exhibit ↗
EX-4.4 (by filename) d128802dex44.htm

EX-4.4 7 d128802dex44.htm EX-4.4 EX-4.4 Exhibit 4.4 NINTH SUPPLEMENTAL INDENTURE THIS NINTH SUPPLEMENTAL INDENTURE (this “Ninth Supplemental Indenture”) dated as of March 23, 2026 between Exact Sciences Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). W I T N E S S E T H : WHEREAS, the Company and the Trustee are parties to an Indenture, dated as of January 17, 2018 (the “Base Indenture”), and the Fifth Supplemental Indenture, dated as of April 17, 2024 (the “Fifth Supplemental Indenture”, together with the Base Indenture, the “2031 Notes Indenture”) providing for the issuance of the 1.75% Convertible Senior Notes due 2031 (the “Notes”); WHEREAS, the Company entered into that certain Agreement and Plan of Merger, dated as of November 19, 2025 (the “Merger Agreement”), by and among the Company, Abbott Laboratories, an Illinois corporation (“Abbott”), and Badger Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Abbott (“Merger Sub”), pursuant to which, on the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub merged with and i…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.